Novartis/Idenix Request Priority Review For Once-Daily Chronic Hepatitis B Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Telbivudine demonstrates significantly greater viral suppression compared to lamivudine in one-year data.
You may also be interested in...
Roche's Pegasys Gains Hepatitis B Indication
FDA clears peginterferon alfa-2a for treatment of HBeAg-positive and negative chronic hepatitis B patients; approval is based on two Phase III head-to-head trials with GlaxoSmithKline's Epivir-HBV. Roche is highlighting Pegasys' limited duration of treatment relative to other hepatitis B therapies.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.